Yun Wu

Yun Wu

Auto-generated profile, based on publicly available information

Yun Wu

Department of Laboratory Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2024 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
YWYun Wu
Yun Wu
JCJiawei Chen
Jiawei Chen
GZGe Zhang
Ge Zhang
JLJin Li
Jin Li
TWTong Wang
Tong Wang
YXYingchun Xu
Yingchun Xu
Carbapenem-resistant bacteria (CRB), including carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), and carbapenem-resistant Enterobacterales (CRE), pose a considerable threat to public health in China. Eravacycline, aztreonam/avibactam, and colistin are important antimicrobial agents for the treatment of serious infections caused by CRB. The study aims to evaluate the prevalence of CRB strains and the susceptibility of commonly used clinical antimicrobial agents against the strains with different carbapenemase genes . We collected 7,194 gram-negative bacteria (GNB) strains from different regions of China and identified 924 carbapenem-resistant strains. All strains were from infections with confirmed diagnoses. Antimicrobial susceptibility testing, covering 21 antimicrobial agents including aztreonam/avibactam, eravacycline, colistin, and other comparators, was performed using the broth microdilution method. Carbapenemase genes (blaKPC, blaNDM, blaOXA, blaIMP, and blaVIM) were screened by PCR amplification and sequence analysis. All statistical analyses were performed using Statistical Package for the Social Sciences version 23.0 software. The isolation rates of CRE, CRAB, and CRPA were 6.31% (332/5265), 62.95% (440/699), and 15.20% (152/1000), respectively. The predominant carbapenemase in carbapenem-resistant Escherichia coli (CRECO) was NDM, while in CRKP it was KPC. All CRAB produced OXA-23 and 85.52 % of CRPA did not produce any of the following carbapenemases: NDM, KPC, VIM, IMP and OXA. Aztreonam/avibactam, colistin, and eravacycline exhibited high antimicrobial activity against different species producing various carbapenemases. Compared to ceftazidime/avibactam, aztreonam/avibactam demonstrated superior antimicrobial activity, particularly pronounced in CRECO and strains producing metallo-beta-lactamases (MBLs). In comparisons between tigecycline and eravacycline, the latter maintained higher antimicrobial activity across different species. Antimicrobial agents exhibited varying levels of activities when against strains with different resistance mechanisms. Our results support the fact that using aztreonam/avibactam, eravacycline, and colistin to treat infections caused by CRB offers significant advantages. These fingdings will guide clinical practice and optimize antimicrobial administration.

4 June 2024 in Microbiology Spectrum
Verified
Journal Article
Open access
YWYun Wu
Yun Wu
WYWei Yu
Wei Yu
XCXiaobing Chu
Xiaobing Chu
JZJingjia Zhang
Jingjia Zhang
PJPeiyao Jia
Peiyao Jia
QYQiwen Yang
Qiwen Yang
This study aimed to assess the in vitro efficacy of ceftazidime-avibactam (CZA) in combination with various antimicrobial agents against carbapenem-resistant Klebsiella pneumoniae (CRKP). We selected 59 clinical CRKP isolates containing distinct drug resistance mechanisms. The minimum inhibitory concentrations (MICs) of meropenem (MEM), colistin (COL), eravacycline (ERA), amikacin (AK), fosfomycin (FOS), and aztreonam (ATM), both individually and in combination with CZA, were tested using the checkerboard method. The interactions of antimicrobial agent combinations were assessed by fractional inhibitory concentration index (FICI) and susceptible breakpoint index (SBPI). The time-kill curve assay was employed to dynamically evaluate the effects of these drugs alone and in combination format. In the checkerboard assay, the combination of CZA+MEM showed the highest level of synergistic effect against both KPC-producing and carbapenemase-non-producing isolates, with synergy rates of 91.3% and 100%, respectively. Following closely was the combination of FOS+CZA . For metallo-beta-lactamases (MBLs) producing strains, ATM+CZA displayed complete synergy, while the combination of MEM+CZA showed a synergy rate of only 57.14% for NDM-producing strains and 91.67% for IMP-producing strains. In the time-kill assay, MEM+CZA also demonstrated significant synergistic effects against the two KPC-2-producing isolates (Y070 and L70), the two carbapenemase-non-producing isolates (Y083 and L093), and the NDM-1-producing strain L13, with reductions in log 10 CFU/mL exceeding 10 compared to the control. Against the IMP-producing strain Y047, ATM+CZA exhibited the highest synergistic effect, resulting in a log 10 CFU/mL reduction of 10.43 compared to the control. The combination of CZA and MEM exhibited good synergistic effects against KPC-producing and non-enzyme-producing strains, followed by the FOS+CZA combination. Among MBL-producing strains, ATM+CZA demonstrated the most pronounced synergistic effect. However, the combinations of CZA with ERA, AK, and COL show irrelevant effects against the tested clinical isolates. IMPORTANCE: Our study confirmed the efficacy of the combination CZA+MEM against KPC-producing and non-carbapenemase-producing strains. For metalloenzyme-producing strains, CZA+ATM demonstrated the most significant synergy. Additionally, CZA exhibited a notable synergy effect when combined with FOS. These combination therapies present promising new options for the treatment of CRKP infection.

7 January 2025 in Microbiology Spectrum
Verified
Journal Article
Open access
JCJiawei Chen
Jiawei Chen
YWYun Wu
Yun Wu
YZYing Zhu
Ying Zhu
LZLi Zhang
Li Zhang
YXYingchun Xu
Yingchun Xu
YLYali Liu
Yali Liu
Staphylococcus aureus is an important human pathogen due to its vast array of virulence factors regulated by multiple regulatory mechanisms, including the accessory gene regulator. In this study, two S . aureus strains were simultaneously isolated from the blood of a febrile patient, belonging to the same clone, designated as 23H with a complete hemolytic phenotype, and 23B, exhibiting an incomplete hemolytic phenotype. The genomic comparison between strains 23B and 23H revealed that 23B had a single adenine base insertion at position 923 in the agrC gene, leading to a functional loss of the encoded AgrC. Experimental findings showed that strain 23B had decreased hemolytic activity, lower cytotoxicity against human alveolar epithelial A549 cells and in the Galleria mellonella model, and a reduced ability to survive intracellularly after infecting macrophages, in comparison to 23H. Conversely, 23B exhibited enhanced biofilm formation, greater adherence to A549 cells, and increased persistence in the face of vancomycin and daptomycin treatment. Transcriptomic analysis revealed that 23B upregulated surface protein-encoding genes while simultaneously reducing the expression levels of virulence factors, highlighting the intricate regulatory adjustments facilitating its persistence and reducing pathogenic potential. ATP assay results indicated that 23B maintained elevated ATP levels during the exponential phase yet exhibited reduced levels in the stationary phase when compared with 23H. Our findings suggested that the mutation in the agrC gene of S. aureus results in diminished virulence but markedly enhances persistence. This mutated strain warrants clinical attention because it may lead to treatment failures and persist in patients. IMPORTANCE: In clinical antimicrobial therapy, bacterial strains often develop resistance to antimicrobial agents. Additionally, mutations in their gene regulatory networks can increase their persistence, especially in immunocompromised patients. This study identified an insertion mutation in the accessory gene regulator, agrC gene, carried by a Staphylococcus aureus strain isolated from the blood of a febrile patient, leading to the functional loss of AgrC. Further research revealed that despite the reduced virulence of the mutated strain, it significantly bolstered the capacity to adapt and endure within the host during prolonged infections. This was evidenced by increased adhesion and biofilm formation capabilities, development of antimicrobial tolerance, and decreased ATP levels linked to persistence. Therefore, monitoring these mutations in S. aureus is crucial clinically, as they can complicate treatment strategies.

1 July 2025 in Microbiology Spectrum
Verified
Journal Article
Open access
YWYun Wu
Yun Wu
AWAixin Wang
Aixin Wang
JQJinghan Qu
Jinghan Qu
RMRuirui Ma
Ruirui Ma
WKWei Kang
Wei Kang
YXYingchun Xu
Yingchun Xu
The aim of the study was to compare in vitro antimicrobial susceptibility between mucoid and non-mucoid Pseudomonas aeruginosa and its guiding value for antibiotic therapy. A retrospective review was conducted on the sources of isolates, patient information, in vitro antimicrobial susceptibility results, and antimicrobial usage records for mucoid and non-mucoid P. aeruginosa isolates spanning from 2021 to 2023, comparing the differences between the two types. Additionally, infection cases of mucoid and non-mucoid P. aeruginosa were selected for in-depth analysis of their treatment courses, evaluating the guiding value of antimicrobial susceptibility results for antimicrobial therapy. We collected 1,443 non-mucoid P. aeruginosa and 342 mucoid P. aeruginosa . Our findings revealed that mucoid P. aeruginosa was predominantly found in respiratory tract specimens, while non-mucoid P. aeruginosa was primarily isolated from a broader range of specimen sources. Regarding antimicrobial susceptibility, mucoid P. aeruginosa exhibited notably lower levels of resistance compared to their non-mucoid counterparts, except for ciprofloxacin, levofloxacin, and cefepime. The most frequently prescribed drugs for mucoid P. aeruginosa were levofloxacin and ceftazidime, whereas for non-mucoid P. aeruginosa, ceftazidime and meropenem were more frequently used. A total of 42 non-mucoid P. aeruginosa cases and 36 mucoid P. aeruginosa cases were further analyzed, which were isolated from hospitalized patients with a confirmed diagnosis of monomicrobial P. aeruginosa infection. The analysis of case information revealed that 90.2% of non-mucoid P. aeruginosa infections and 94.4% of mucoid P. aeruginosa infections showed consistency between in vitro antimicrobial susceptibility and outcomes. Our results revealed differences in demographic and clinical characteristics, antimicrobial susceptibility, and selection of antimicrobial agents between mucoid and non-mucoid P. aeruginosa . The findings will help optimize prognosis and combat the challenges posed by P. aeruginosa infections. IMPORTANCE: This study represents a large-scale comparative research conducted over two years at a tertiary hospital in China, involving 1,443 non-mucoid and 342 mucoid strains. We found significant differences between mucoid and non-mucoid P . aeruginosa infections in terms of gender, antimicrobial susceptibility test, and the selection of antimicrobial agents. Specifically, mucoid P. aeruginosa infections were predominantly observed in females and were mainly associated with respiratory tract infections. Moreover, the isolates with mucoid phenotype exhibited higher susceptibility to most antimicrobial agents compared to non-mucoid isolates. According to the data of the pharmacy department, we found the most frequently prescribed drugs for mucoid P. aeruginosa were levofloxacin and ceftazidime, whereas for non-mucoid P. aeruginosa , ceftazidime and meropenem were more frequently used. The analysis of case information revealed that no matter whether in mucoid or non-mucoid P. aeruginosa , the in vitro antimicrobial susceptibility test results were in good agreement with the therapeutic outcomes.

4 July 2026 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
YWYun Wu
Yun Wu
MZMenglan Zhou
Menglan Zhou
LZLi Zhang
Li Zhang
TJTaiyi Jiang
Taiyi Jiang
YXYingchun Xu
Yingchun Xu